

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Baseline patient characteristics.

Parameter	N=32
Women n (%)	23 (72)
Age (mean \pm SD)	53.1 \pm 14.3
BMI (mean \pm SD)	29.5 \pm 7
Smoking	
Never smoker, n (%)	22 (68.7)
Ex-smoker, n (%)	9 (28.1)
Smoker, n (%)	1 (3.1)
Age onset symptoms	
0 – 18y, n (%)	8 (25)
> 18y, n (%)	28 (75)
Atopy, n (%)	19 (59.4)
Rhinosinusitis, n (%)	6 (18.7)
Corticosteroid-dependent, n (%)	3 (9.4)
Eosinophils (mean \pm SD)	387 \pm 592
IgE (mean \pm SD)	244 \pm 286
FeNO (mean \pm SD)	30.6 \pm 21.9
ACT (mean \pm SD)	11.4 \pm 3,7
AQLQ (mean \pm SD)	3,1 \pm 1
Exacerbations (mean \pm SD)	2.8 \pm 2.8
\geq 1 ED visit n (%)	21 (65.6%)
\geq 1 Hospital admission n (%)	6 (18,7%)
FVC ml (mean \pm SD)	2752 \pm 870
FVC % (mean \pm SD)	77.2 \pm 17.9
FVC Zscore	- 1.68 \pm 1.22
FEV1 ml (mean \pm SD)	2031 \pm 130
FEV1 % (mean \pm SD)	71.4 \pm 18,2
FEV1 ZScore	- 1.98 \pm 0.94
Prior treatment with a biologic agent	
Omalizumab, n (%)	9 (28.1%)
Mepolizumab, n (%)	9 (28.1%)
Benralizumab, n (%)	4 (12.5%)
Dupilumab, n (%)	3 (9.4%)

Two patients were previously treated with Omalizumab and Mepolizumab, one patient with Omalizumab and Benralizumab, one patient with Omalizumab, Mepolizumab, and Dupilumab, and one patient with Omalizumab, Mepolizumab, Benralizumab, and Dupilumab.

All the previous biological treatments were stopped due to a therapeutic failure, except one patient who stopped Dupilumab due to adverse effects (arthromyalgia).